SRX251 is a mechanism-based breakthrough drug that reduces or eliminates the short- and long-term effects of non-penetrating mild and moderate Traumatic Brain Injuries. A selective vasopressin 1a receptor antagonist, SRX251 targets a pathway that underlies the brain damage, cognitive effects, and long-term risks from these injuries.
Primary Application Area: Medical Devices & Materials
Technology Development Status: Proven Manufacturability
Technology Readiness Level: TRL 7
Organization Type: Mid-stage Startup (A or B)
Market Keywords: Traumatic Brain Injury, Emergency & Primary Physicians, Point-of-Injury treatment